Compare Estee Lauder Companies Inc (EL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Natera Inc. Common Stock — how do they compare? Estee Lauder Companies Inc trades at $101.8 (market cap $36.13B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.4% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 123 Days and Natera Inc. Common Stock for 0 Days on average.
| EL | NTRA | |
|---|---|---|
Market Cap | $36.13B | $57.03B |
Volume | 1,925,948 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $425.64 |
52-Week Low | $67.23 | $179.42 |
Typical Hold Time | 123 Days | 0 Days |
Enterprise Value | $41.88B | $56.18B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $101.59, up 1.55% with strong technical momentum and bullish moving average signals. The company shows improving operational trends with three consecutive quarterly earnings beats, though 2025 results reflect a net loss of $1.13B amid revenue contraction. Recent strategic partnerships in AI marketing and leadership appointments signal transformation efforts, while analyst consensus remains positive with a $103 price target.
The stock presents a turnaround opportunity with margin recovery potential and digital innovation initiatives, but faces execution risks from competitive pressures and debt levels. Current valuation multiples appear elevated relative to profitability metrics, requiring careful monitoring of Q3 2026 earnings delivery for confirmation of sustained improvement.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
